Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-32024795

ABSTRACT

OBJECTIVE: To compare the reproducibility of 11 antibody assays for immunoglobulin (Ig) G and IgM myelin oligodendrocyte glycoprotein antibodies (MOG-IgG and MOG-IgM) from 5 international centers. METHODS: The following samples were analyzed: MOG-IgG clearly positive sera (n = 39), MOG-IgG low positive sera (n = 39), borderline negative sera (n = 13), clearly negative sera (n = 40), and healthy blood donors (n = 30). As technical controls, 18 replicates (9 MOG-IgG positive and 9 negative) were included. All samples and controls were recoded, aliquoted, and distributed to the 5 testing centers, which performed the following antibody assays: 5 live and 1 fixed immunofluorescence cell-based assays (CBA-IF, 5 MOG-IgG, and 1 MOG-IgM), 3 live flow cytometry cell-based assays (CBA-FACS, all MOG-IgG), and 2 ELISAs (both MOG-IgG). RESULTS: We found excellent agreement (96%) between the live CBAs for MOG-IgG for samples previously identified as clearly positive or negative from 4 different national testing centers. The agreement was lower with fixed CBA-IF (90%), and the ELISA showed no concordance with CBAs for detection of human MOG-IgG. All CBAs showed excellent interassay reproducibility. The agreement of MOG-IgG CBAs for borderline negative (77%) and particularly low positive (33%) samples was less good. Finally, most samples from healthy blood donors (97%) were negative for MOG-IgG in all CBAs. CONCLUSIONS: Live MOG-IgG CBAs showed excellent agreement for high positive and negative samples at 3 international testing centers. Low positive samples were more frequently discordant than in a similar comparison of aquaporin-4 antibody assays. Further research is needed to improve international standardization for clinical care.


Subject(s)
Autoantibodies/blood , Biological Assay/standards , Enzyme-Linked Immunosorbent Assay/standards , Flow Cytometry/standards , Fluorescent Antibody Technique/standards , Immunoglobulin G/blood , Immunoglobulin M/blood , Multicenter Studies as Topic/standards , Myelin-Oligodendrocyte Glycoprotein/immunology , Humans , Reproducibility of Results
2.
Proteomics Clin Appl ; 12(6): e1800007, 2018 11.
Article in English | MEDLINE | ID: mdl-29952123

ABSTRACT

PURPOSE: Increasing incidence of onychomycosis and tinea pedis in humans of industrialized countries together with deep tissue infections are a therapeutic challenge in clinical mycology. For a better understanding of the pathology and immunology of infection, the authors analyze the exoproteomes of three reference strains of the most common clinical dermatophyte species (Trichophyton rubrum, Trichophyton interdigitale, Arthroderma benhamiae) and of Trichophyton strains isolated from affected patients. EXPERIMENTAL DESIGN: Extracellular proteins of those in vitro grown strains are separated via 2D High Performance Electrophoresis and identified by mass spectrometry to find proteins with provoked host immune reactivity. RESULTS: More than 80 secreted proteins including virulence factors such as peptidases and other hydrolases are identified. By Western blotting with respective patient sera, up to 31 proteins with significant antigen-antibody reactions are detected in comparison with control sera, for example, peptidases as well as several oxidoreductases. One protein, beta-glucosidase F2SZI9 seems to be a commonly processed antigen in all Trichophyton infections. CONCLUSIONS AND CLINICAL RELEVANCE: These first global exoproteome data of three dermatophyte species can be a stepping stone on the way to further study the molecular mechanisms of Trichophyton pathogenicity-associated traits. Possible candidates for potential new diagnostic methods or vaccination have to be validated in further investigations.


Subject(s)
Antigens, Fungal/genetics , Tinea/genetics , Trichophyton/genetics , beta-Glucosidase/genetics , Antigens, Fungal/immunology , Antigens, Fungal/isolation & purification , Female , Humans , Male , Proteins/genetics , Proteins/isolation & purification , Proteome/genetics , Tinea/immunology , Tinea/microbiology , Tinea/pathology , Trichophyton/immunology , Trichophyton/pathogenicity , beta-Glucosidase/immunology , beta-Glucosidase/isolation & purification
3.
Proc Natl Acad Sci U S A ; 100(5): 2444-9, 2003 Mar 04.
Article in English | MEDLINE | ID: mdl-12604780

ABSTRACT

FAP48 was identified and cloned thanks to its interaction with FK506-binding proteins (FKBPs) such as FKBP52 and FKBP12, which belong to the large family of immunophilins that bind the macrolide immunosuppressant drugs FK506 and rapamycin. We have previously shown that FAP48-FKBP complexes are dissociated by FK506 and rapamycin, suggesting that FAP48 is an endogenous ligand of FKBP. The present work describes the biochemical consequences of FAP48 overexpression, induced by the tetracycline analogue doxycycline, in an established cell line derived from Jurkat T cells. We report that overexpression of FAP48 results in the inhibition of cellular proliferation as does the exposure of Jurkat T cells to FK506. We also show that the expression levels of argininosuccinate synthetase and the Myc antagonist Mxi1 are modified by overexpression of FAP48, suggesting that these proteins could be good candidates to mediate the antiproliferative effect of FAP48. FAP48 affects neither the calcineurin-dependent nuclear factor of activated T cells (NFAT)1 nor JNKp38-dependent pathways that mediate immunosuppression by FK506. However, contrary to FK506, which blocks IL2 synthesis, we observed that FAP48-FKBP complexes increase IL2 production, thus revealing a previously uncharacterized aspect of the immunosuppressive mechanism of FK506.


Subject(s)
Adaptor Proteins, Signal Transducing , Interleukin-2/metabolism , Nuclear Proteins , T-Lymphocytes/cytology , Tacrolimus Binding Proteins/chemistry , Anti-Bacterial Agents/pharmacology , Basic Helix-Loop-Helix Transcription Factors , Cell Division/drug effects , Cell Separation , Cloning, Molecular , DNA/metabolism , DNA-Binding Proteins/metabolism , Down-Regulation , Doxycycline/pharmacology , Flow Cytometry , Humans , Immunosuppressive Agents/pharmacology , Jurkat Cells , Ligands , Models, Biological , NFATC Transcription Factors , Precipitin Tests , Protein Binding , Tacrolimus Binding Proteins/genetics , Tacrolimus Binding Proteins/metabolism , Time Factors , Transcription Factors/metabolism , Transfection , Tumor Suppressor Proteins
4.
Biochemistry ; 41(8): 2760-8, 2002 Feb 26.
Article in English | MEDLINE | ID: mdl-11851423

ABSTRACT

The estrogen receptor (ER) plays a critical role in the development of hormone-dependent cancer. Since HMGA1, a member of the "high mobility group" proteins, is overexpressed in certain malignant cells, we investigated the interaction between these nuclear proteins. Transfection of the HMGA1 expression vector increased 2-fold the transcriptional activation of ERE containing promoter by E(2). Furthermore, the HMGA1 protein stimulated severalfold the binding of purified ER to the consensus ERE oligonucleotides in gel mobility shift assays and saturation assays. However, HMGA1 could not bind alone either to consensus or to modified EREs, and the minor groove binding drug distamycin A failed to prevent the synergism between ER and HMGA1. This could suggest that the binding of HMGA1 to DNA was not required for its stimulatory effect. Antibody supershift assays showed that HMGA1 was required for increased binding and suggest a protein-protein interaction between those factors. This was confirmed by pull down assay. These data show that HMGA1 acts in concert with the ER to regulate the expression of estrogen responsive genes through a mechanism that does not require direct binding to DNA. These observations may be relevant in malignant cells expressing both proteins.


Subject(s)
High Mobility Group Proteins/physiology , Receptors, Estrogen/metabolism , Transcription, Genetic/physiology , Base Sequence , Binding Sites , DNA Probes , Electrophoretic Mobility Shift Assay , High Mobility Group Proteins/metabolism , Humans , Promoter Regions, Genetic , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...